debt_leverage_profile
Pre-revenue biotech; minimal debt, equity-financed via grants and private placements; near-zero leverage ratio
Inferred
Agent_Inference
interest_rate_sensitivity
Negligible direct sensitivity; no significant debt obligations, but higher rates increase cost of future equity dilution rounds
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Israel-based R&D (geopolitical risk in Middle East); specialized polymer/biopolymer inputs sourced from limited global suppliers
Inferred
Agent_Inference
international_expansion_readiness
No meaningful international revenue yet; early-stage pipeline; currency devaluation exposure effectively nil at current commercialization stage
Inferred
Agent_Inference
geographic_footprint
Primarily Israel HQ; early US regulatory engagement; no multi-market revenue footprint yet to create material FX devaluation exposure
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Dependency on specialized biopolymer and hydrogel material suppliers; substitutability is moderate but switching requires re-validation under regulatory frameworks
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption impact low; core IP is physical nasal/ocular drug-delivery gel technology, not software-defined infrastructure
Inferred
Agent_Inference
business_model_type_secondary
Platform licensing and partnership model with pharma companies; not cloud-native, so AWS/GCP/Azure termination has minimal operational impact
Inferred
Agent_Inference
switching_cost_profile
Minimal API coupling risk; product is biotech/medtech hardware-adjacent; regulatory re-approval creates switching costs for pharma partners
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is pharma licensing/milestone payments, not token-based or investment-contract structured
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure; clinical trial data handled under GCP frameworks; no consumer data monetization identified
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche nasal/ocular delivery platform with small market share and no dominant market position currently
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Primarily milestone-based licensing; recurring revenue near-zero at current stage; transactional/event-driven milestone payments dominate
Inferred
Agent_Inference
monetization_vector
Pharma partnership licensing fees, R&D milestone payments, and eventual royalties on commercialized products post-approval
Inferred
Agent_Inference
pricing_architecture
Milestone and royalty pricing tied to clinical success gates; limited pricing power until first commercial approval achieved
Inferred
Agent_Inference
pricing_power_rating
Moderate long-term pricing power if platform validated; currently weak given pre-revenue status and pharma partner negotiation leverage
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margins 70-85% at scale via royalty/licensing model; current margins not meaningful given pre-commercialization stage
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage issue; proprietary gel technology is patent-protected; open-access risk low in regulated pharma context
Inferred
Agent_Inference
headcount_cost_structure
R&D-heavy, headcount-sublinear at scale; licensing model allows revenue multiplication without proportional headcount growth
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is low once platform validated; incremental licensing deals require minimal additional R&D or headcount
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
CAC not publicly disclosed; pharma BD-driven acquisition; at 10x scale, unit economics improve significantly via royalty leverage
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; value grows via clinical data accumulation and platform credibility, not user-to-user network dynamics
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low; physical biopolymer formulation and regulatory expertise not easily automated or AI-substituted
Inferred
Agent_Inference
recession_resistance_tier
Moderate resilience; pharma R&D budgets can contract in recession, but unmet medical need pipeline provides some insulation
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical and biotech companies seeking drug delivery enhancement for nasal and ocular administration routes
Inferred
Agent_Inference
customer_segment_secondary
Potential government/military biodefense clients for nasal-barrier protective applications (BioProtect platform)
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated toward clinical-stage validation and regulatory milestones; no legacy infrastructure drag; future-state focused R&D spend
Inferred
Agent_Inference
sec_cik
0001893645
High
SEC-EDGAR
ticker
PLRZ
High
SEC-EDGAR